What is the rationale for switching from a 24‑2 visual‑field test to a 10‑2 visual‑field test in subsequent visits?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Switching from 24-2 to 10-2 Visual Field Testing

The 10-2 visual field test should be added when you need to detect early central visual field damage that the 24-2 test misses, particularly when structural testing (OCT) shows macular or central retinal nerve fiber layer thinning, or when the 24-2 shows 5 or more defective central test locations. 1

Primary Rationale for Adding 10-2 Testing

The fundamental issue is that the 24-2 test has insufficient spatial sampling density in the central 10 degrees to detect early macular damage. The American Academy of Ophthalmology guidelines explicitly state that the 10-2 program is useful to detect early visual field damage in the central 10 degrees before such abnormalities are obvious in a 24- or 30-degree testing strategy 1. This is not merely theoretical—research demonstrates that 41.8% of eyes with confirmed macular damage (verified by both 10-2 and OCT) were missed by the 24-2 test, with individual 24-2 metrics missing between 12% to 34% of these cases 2.

Specific Clinical Triggers for Switching

When to Add 10-2 Testing:

  • Structural-functional mismatch: When OCT shows macular ganglion cell complex or retinal nerve fiber layer thinning but the 24-2 appears normal or only mildly abnormal
  • Five or more defective central locations on 24-2: This threshold indicates a "functional vulnerability zone" where 10-2 provides additional clinical dynamic range for monitoring 3
  • 24-2 mean deviation between -3 to -6 dB: This range represents early to moderate damage where central field assessment becomes critical 3
  • Patients at risk for faster central progression: Those with worse baseline central visual field loss benefit most from 10-2 monitoring 4

Advantages of 10-2 Testing

Detection Capabilities:

  • Lower variability: The 10-2 consistently shows lower test-retest variability compared to 24-2, particularly in the -5 to -20 dB range 5
  • Faster progression detection: Time to detect confirmed progression at 80% power is reduced by 14.6-18.5% with 10-2 compared to 24-2 5
  • Residual function detection: The 10-2 can identify preserved visual function in areas that appear completely damaged on 24-2 (0 dB sensitivity) 6

Spatial Resolution:

The 10-2 test provides higher spatial sampling density in the central macula, which is critical because:

  • Glaucomatous damage frequently affects the macula early in disease
  • The 24-2 test points are too widely spaced (6 degrees apart) to adequately sample the central field
  • Shallow and deep local defects in the macula are commonly missed by 24-2 2

Practical Implementation Strategy

Do not replace the 24-2 with 10-2—the guidelines emphasize that testing strategies should be tailored to the patient and degree of visual field loss 1. Instead:

  1. Continue 24-2 testing to monitor the entire visual field
  2. Add 10-2 testing when clinical triggers are met
  3. Alternate testing patterns if testing burden is a concern (e.g., 24-2 one visit, 10-2 the next)
  4. Use both tests for patients with confirmed central damage or at high risk for central progression

Important Caveats

  • Not a screening tool: The 10-2 should not be used as the initial or sole visual field test—it complements rather than replaces the 24-2
  • Test burden: Adding 10-2 increases patient testing time and fatigue; consider alternating patterns or using newer adaptive approaches 7
  • Interpretation context: Results must be interpreted alongside clinical examination, OCT findings, and 24-2 results—no single test provides complete information 1
  • Confirmation needed: When newly detected glaucomatous damage appears on either test, repeat testing to confirm the change 1

Quality of Life Impact

The central 10 degrees of vision is disproportionately important for quality of life—it encompasses fixation and reading vision. Detecting and monitoring central field loss early allows for more aggressive treatment to preserve the most functionally critical visual field area, directly impacting patients' ability to read, recognize faces, and maintain independence. Missing central progression while monitoring only peripheral fields can result in irreversible loss of these critical functions.

References

Related Questions

Is co-amoxiclav (amoxicillin‑clavulanate) appropriate for treating streptococcal pharyngitis and septic arthritis in a child, and what dosing should be used?
Is the inactivated rabies vaccine safe and indicated for use in pregnant women who have been exposed to a potentially rabid animal or require pre‑exposure prophylaxis?
Which anatomical features in children contribute to the atypical presentation of acute appendicitis?
In a 54-year-old male with a negative Cologuard stool DNA test performed four years ago, what is the next recommended colorectal cancer screening test?
What is the appropriate workup and management for a patient presenting with glossitis?
What is the appropriate post‑exposure prophylaxis for hepatitis C virus (HCV) exposure, including recommended antiviral regimen and monitoring?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.